Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens

Investigator: Polly Niravath, MD

Study Coordinator: Lacey Burey

Status: Enrolling

ClinicalTrials.gov Number: NCT03901339

Phone: 713.441.1159

Protocol Number: Pro00023091

Description

This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease.
More to Explore
Live Chat Available